Affiliation:
1. Departamento de Microbiología y Patología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico
2. Coordinación de Calidad de Insumos y Laboratorios Especializados, Instituto Mexicano del Seguro Social, Ciudad de Mexico 07760, Mexico
Abstract
SARS-CoV-2 is the causal agent of COVID-19; the first report of SARS-CoV-2 infection was in December 2019 in Wuhan, China. This virus has since caused the largest pandemic in history, and the number of deaths and infections has been significant. Nevertheless, the development of vaccines has helped to reduce both deaths and infections. Comorbidities such as diabetes, hypertension, heart and lung diseases, and obesity have been identified as additional risk factors for infection and the progression of COVID-19. Additionally, latent toxoplasmosis has been reported to be a risk factor for acquiring COVID-19 in some studies, but other studies have suggested a negative association between these two infections. Furthermore, in patients after vaccination or with COVID-19 and coinfection, an increase in the lethality and mortality of toxoplasmosis has been observed. Therefore, the objective of the current study is to determine the association of toxoplasmosis with COVID-19 in patients diagnosed with COVID-19. Serum samples from 384 patients previously diagnosed with COVID-19 using IgG antibodies against the S1/S2 antigens of SARS-CoV-2 were collected. Subsequently, anti-Toxoplasma IgG and IgM antibodies were analyzed with ELISA. Statistical analysis was performed using SPSS Version 20.0 frequencies, percentages, 2 × 2 tables, and the Pearson correlation coefficient. IgG and IgM anti-Toxoplasma antibodies were positive in 105/384 (27.34%) and (26/191) 13.6% of patients, respectively. The positivity for both infections was higher in patients aged >40 years old. Subjects who were overweight or obese were mainly positive for both IgG antibodies against S1/S2 SARS-CoV-2 and Toxoplasma antibodies. In conclusion, the coinfection rate was 21.7%. The prevalence of S1/S2 SARS-CoV-2 was 308/384 (80.2%), and the percentage of Toxoplasma antibodies was 27.34%.
Funder
Program to Support the Improvement of the Production Conditions of the SNI and SNCA Members (PRO-SNI) of the University of Guadalajara
Coordinación de Calidad de Insumos y Laboratorios Especializados, Instituto Mexicano del Seguro Social. A.G.S.-L.
Subject
Virology,Microbiology (medical),Microbiology
Reference45 articles.
1. Occupational risks for COVID-19 infection;Koh;Occup. Med.,2020
2. Comorbidity and its Impact on Patients with COVID-19;Sanyaolu;SN Compr. Clin. Med.,2020
3. Muñoz-Medina, J.E., Grajales-Muñiz, C., Salas-Lais, A.G., Fernandes-Matano, L., López-Macías, C., Monroy-Muñoz, I.E., Santos Coy-Arechavaleta, A., Palomec-Nava, I.D., Duque-Molina, C., and Madera-Sandoval, R.L. (2021). SARS-CoV-2 IgG Antibodies Seroprevalence and Sera Neutralizing Activity in MEXICO: A National Cross-Sectional Study during 2020. Microorganisms, 9.
4. Organización Mundial de la Salud (2023, April 04). COVID-19: Cronología de la Actuación de la OMS. Available online: https//covid19.who.int.
5. Características clínicas y comorbilidades asociadas a mortalidad en pacientes con COVID-19 en Coahuila (Mexico) [Clinical characteristics and comorbidities associated with mortality in patients with COVID-19 in Coahuila (Mexico)];Rev. Clin. Esp.,2021
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献